| 日付 |
時間 |
ソース |
タイトル |
|---|
| 2023/12/01 | 07:00 | BW | FDA Grants Priority Review to Merck’s Application for.. |
| 2023/11/29 | 23:00 | BW | AWS and Accenture Help Merck Use Cloud Technology to Reduce.. |
| 2023/11/29 | 06:51 | EDGAR2 | Form 8-K - Current report |
| 2023/11/29 | 04:10 | DJN | Merck Raises Quarterly Dividend 5.5% To 77 Cents |
| 2023/11/29 | 03:17 | BW | Merck Announces First-Quarter 2024 Dividend |
| 2023/11/28 | 20:45 | BW | Merck’s V116, an Investigational, 21-valent Pneumococcal.. |
| 2023/11/21 | 20:45 | BW | Merck to Acquire Caraway Therapeutics, Inc. |
| 2023/11/20 | 20:45 | BW | Merck to Participate in the 6th Annual Evercore ISI.. |
| 2023/11/17 | 21:45 | IHMARKETNEWS | Friday’s Wall Street Highlights: Applied Materials,.. |
| 2023/11/17 | 07:40 | BW | FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus.. |
| 2023/11/13 | 21:36 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 2023/11/10 | 22:35 | DJN | Merck Gets CHMP Backing for Keytruda in Biliary Tract Cancer |
| 2023/11/10 | 21:40 | BW | Merck Receives Positive EU CHMP Opinion for KEYTRUDA®.. |
| 2023/11/10 | 07:05 | EDGAR2 | Form 144 - Report of proposed sale of securities |
| 2023/11/09 | 23:04 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 2023/11/09 | 06:38 | EDGAR2 | Form 144 - Report of proposed sale of securities |
| 2023/11/08 | 20:45 | BW | Merck to Participate in the Jefferies London Healthcare.. |
| 2023/11/04 | 05:10 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2023/11/02 | 04:49 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 2023/11/01 | 19:50 | BW | Merck to Participate in the UBS BioPharma Conference |
| 2023/11/01 | 19:45 | BW | FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus.. |
| 2023/11/01 | 19:30 | BW | KEYTRUDA® (pembrolizumab) Significantly Improved Overall.. |
| 2023/11/01 | 00:08 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
| 2023/10/30 | 21:45 | IHNW | Can Diabetes, Weight-Loss Drugs Get Even Better? |
| 2023/10/26 | 21:05 | DJN | Merck 3Q Profit Rose as Sales of Breast Cancer Treatment.. |
| 2023/10/26 | 20:08 | IHMARKETNEWS | Thursday’s Wall Street Highlights: Ford, Morgan Stanley,.. |
| 2023/10/26 | 19:38 | EDGAR2 | Form 8-K - Current report |
| 2023/10/26 | 19:30 | BW | Merck Announces Third-Quarter 2023 Financial Results |
| 2023/10/25 | 20:30 | PRNCA | KEYTRUDA® (pembrolizumab) en association avec LENVIMA®.. |
| 2023/10/22 | 23:30 | BW | KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab.. |
| 2023/10/21 | 21:45 | BW | Merck’s WELIREG® (belzutifan) Significantly Improved.. |
| 2023/10/21 | 03:37 | DJN | Trending: Merck, Daiichi Sankyo Sign Development,.. |
| 2023/10/20 | 23:00 | BW | Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent.. |
| 2023/10/20 | 21:02 | BW | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed.. |
| 2023/10/20 | 21:01 | BW | KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy.. |
| 2023/10/20 | 21:00 | BW | KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery.. |
| 2023/10/20 | 20:22 | IHMARKETNEWS | Friday’s Wall Street Highlights: SolarEdge, Intuitive.. |
| 2023/10/20 | 09:30 | DJN | Merck, Daiichi Sankyo Ink Commercialization Deal for Up to.. |
| 2023/10/20 | 08:30 | BW | Daiichi Sankyo and Merck Announce Global Development and.. |
| 2023/10/17 | 19:45 | BW | Merck Receives Positive EU CHMP Opinion for PREVYMIS® for.. |
| 2023/10/17 | 08:55 | DJN | Merck Gets FDA Approval for Resectable Lung Cancer Treatment.. |
| 2023/10/17 | 08:00 | BW | FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of.. |
| 2023/10/16 | 19:45 | BW | European Commission Approves KEYTRUDA® (pembrolizumab) as.. |
| 2023/10/13 | 20:45 | BW | Merck Receives Positive EU CHMP Opinion for KEYTRUDA®.. |
| 2023/10/10 | 20:17 | DJN | Merck: Phase 3 Keytruda Study Hits Second Goal in Non-Small.. |
| 2023/10/10 | 19:45 | BW | Merck Highlights Innovative Oncology Portfolio and Pipeline.. |
| 2023/10/10 | 19:30 | BW | Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary.. |
| 2023/10/05 | 20:47 | DJN | Merck Keytruda Study Hits Key Goal in Advanced Bladder.. |
| 2023/10/05 | 20:00 | BW | Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of.. |
| 2023/10/05 | 19:45 | BW | Merck to Hold Third-Quarter 2023 Sales and Earnings.. |
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
